{"id":11712,"date":"2025-09-07T16:10:39","date_gmt":"2025-09-07T16:10:39","guid":{"rendered":"https:\/\/revistatrend.com\/?p=11712"},"modified":"2025-09-07T16:10:39","modified_gmt":"2025-09-07T16:10:39","slug":"rusia-pretendon-qe-ka-gati-vaksinen-kunder-kancerit-testet-e-enteromix-dalin-pozitive","status":"publish","type":"post","link":"https:\/\/revistatrend.com\/index.php\/2025\/09\/07\/rusia-pretendon-qe-ka-gati-vaksinen-kunder-kancerit-testet-e-enteromix-dalin-pozitive\/","title":{"rendered":"Rusia pretendon q\u00eb ka gati vaksin\u00ebn kund\u00ebr kancerit: Testet e \u201cEnteromix\u201d dalin pozitive!"},"content":{"rendered":"<p>Rusia thuhet se ka zhvilluar vaksin\u00ebn e par\u00eb kund\u00ebr kancerit, e cila u \u00ebsht\u00eb administruar pacient\u00ebve dhe rezultatet jan\u00eb shum\u00eb inkurajuese. <span style=\"font-size: 14px;\">Trajtimi, i cili \u00ebsht\u00eb zhvilluar si nj\u00eb vaksin\u00eb mRNA, quhet \u201cEnteromix\u201d. Vaksina e re ruse ka p\u00ebrfunduar me sukses provat klinike, duke arritur 100% efektivitet dhe siguri.<\/span><\/p>\n<p>Konkretisht, sipas mediave nd\u00ebrkomb\u00ebtare, trajtimi, i cili jo vet\u00ebm sulmon dhe neutralizon qelizat kancerogjene, por edhe zvog\u00eblon tumoret e m\u00ebdha, tani \u00ebsht\u00eb duke pritur miratimin p\u00ebrfundimtar nga Ministria Ruse e Sh\u00ebndet\u00ebsis\u00eb, n\u00eb m\u00ebnyr\u00eb q\u00eb t\u2019u vihet n\u00eb dispozicion pacient\u00ebve.<\/p>\n<p>Alexander Ginzburg, drejtor i Qendr\u00ebs Komb\u00ebtare t\u00eb K\u00ebrkimeve p\u00ebr Epidemiologjin\u00eb dhe Mikrobiologjin\u00eb (NF Gamalei), n\u00eb fillim t\u00eb gushtit njoftoi fillimin e administrimit t\u00eb vaksin\u00ebs tek pacient\u00eb t\u00eb caktuar, e cila \u00ebsht\u00eb zhvilluar bazuar n\u00eb informacionin gjenetik personal t\u00eb secilit pacient dhe ka t\u00eb b\u00ebj\u00eb konkretisht me pacient\u00ebt me kancer.<\/p>\n<p>Enteromix bazohet n\u00eb teknologjin\u00eb inovative t\u00eb mRNA-s\u00eb, t\u00eb ngjashme me at\u00eb t\u00eb p\u00ebrdorur n\u00eb vaksinat kund\u00ebr COVID-19. Mekanizmi i saj \u00ebsht\u00eb t\u00eb \u201cst\u00ebrvit\u00eb\u201d sistemin imunitar p\u00ebr t\u00eb njohur dhe shkat\u00ebrruar qelizat kancerogjene.<\/p>\n<div class=\"jnews_inline_related_post_wrapper left\">\n<div class=\"jnews_inline_related_post\">\n<div class=\"jeg_postblock_29 jeg_postblock jeg_module_hook jeg_pagination_disable jeg_col_2o3 jnews_module_1596147_1_68bda81d8d63d   \" data-unique=\"jnews_module_1596147_1_68bda81d8d63d\">\n<div class=\"jeg_block_heading jeg_block_heading_6 jeg_subcat_right\"><\/div>\n<div class=\"jeg_block_container\">\n<div class=\"jeg_posts \">\n<div class=\"jeg_postsmall jeg_load_more_flag\">\n<article class=\"jeg_post jeg_pl_xs format-standard\">\n<div class=\"jeg_postblock_content\">\n<h3 class=\"jeg_post_title\"><span style=\"font-size: 14px; color: #333333;\">Ndryshe nga metodat tradicionale, si\u00e7 jan\u00eb kimioterapia dhe radioterapia, vaksina \u00ebsht\u00eb e personalizuar p\u00ebr secilin pacient, duke p\u00ebrb\u00ebr\u00eb nj\u00eb trajtim t\u00eb synuar dhe m\u00eb pak t\u00eb r\u00ebnd\u00eb kund\u00ebr kancerit. \u00cbsht\u00eb e r\u00ebnd\u00ebsishme t\u00eb theksohet se nuk u raportuan efekte an\u00ebsore serioze, dhe pacient\u00ebt e toleruan trajtimin pa probleme.<\/span><\/h3>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>Ginzburg deklaroi n\u00eb fillim t\u00eb gushtit se, sipas planit t\u00eb miratuar nga Ministria Ruse e Sh\u00ebndet\u00ebsis\u00eb, vaksina do t\u00eb administrohet eksperimentalisht tek nj\u00eb grup pacient\u00ebsh me melanom\u00eb n\u00eb bashk\u00ebpunim me Institutin K\u00ebrkimor Shkencor Onkologjik t\u00eb Mosk\u00ebs \u201cGertsen\u201d dhe Qendr\u00ebn Komb\u00ebtare t\u00eb K\u00ebrkimeve Mjek\u00ebsore t\u00eb Onkologjis\u00eb \u201cBlokhin\u201d.<\/p>\n<p>Alexander Ginzburg tha se Qendra Gamalei \u00ebsht\u00eb e angazhuar ekskluzivisht n\u00eb prodhimin e vaksin\u00ebs, e cila bazohet n\u00eb \u201cneoantigjene\u201d t\u00eb hartuara posa\u00e7\u00ebrisht p\u00ebr secilin pacient, informojn\u00eb\u00a0mediat\u00a0e huaja.<\/p>\n<p>M\u00eb par\u00eb, zhvillimi i nj\u00eb vaksine t\u00eb re terapeutike p\u00ebr t\u00eb trajtuar format serioze t\u00eb kancerit u njoftua nga Qendra Federale Klinike Shkencore e Radiologjis\u00eb Mjek\u00ebsore dhe Onkologjis\u00eb e Rusis\u00eb n\u00eb qytetin e Dimitrovgradit.<\/p>\n<p>Ginzburg theksoi se Rusia k\u00ebrkon ta ofroj\u00eb k\u00ebt\u00eb vaksin\u00eb falas p\u00ebr qytetar\u00ebt rus\u00eb dhe provat klinike p\u00ebr t\u00eb zgjedhur pjes\u00ebmarr\u00ebsit e par\u00eb filluan n\u00eb dhjetor 2024. \/<a href=\"https:\/\/economictimes.indiatimes.com\/news\/international\/world-news\/russian-vaccine-for-colon-cancer-ready-to-use-report\/articleshow\/123745291.cms?from=mdr\">The Economic Times<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Rusia thuhet se ka zhvilluar vaksin\u00ebn e par\u00eb kund\u00ebr kancerit, e cila u \u00ebsht\u00eb administruar pacient\u00ebve dhe rezultatet jan\u00eb shum\u00eb inkurajuese. Trajtimi, i cili \u00ebsht\u00eb zhvilluar si nj\u00eb vaksin\u00eb mRNA, quhet \u201cEnteromix\u201d. Vaksina e re ruse ka p\u00ebrfunduar me sukses provat klinike, duke arritur 100% efektivitet dhe siguri. Konkretisht, sipas mediave nd\u00ebrkomb\u00ebtare, trajtimi, i cili<\/p>\n","protected":false},"author":1,"featured_media":11713,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":{"0":"post-11712","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-lifestyle"},"_links":{"self":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts\/11712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/comments?post=11712"}],"version-history":[{"count":1,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts\/11712\/revisions"}],"predecessor-version":[{"id":11714,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/posts\/11712\/revisions\/11714"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/media\/11713"}],"wp:attachment":[{"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/media?parent=11712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/categories?post=11712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/revistatrend.com\/index.php\/wp-json\/wp\/v2\/tags?post=11712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}